Taurine is subtle. Most users report nothing acute. The effect is what doesn't happen — slightly less wired feeling on caffeine, slightly easier wind-down at night, slightly better cardio tolerance during long sets. Onset is poorly characterized but plasma peak ~1-2 hours; effects on sleep typically reported by users at 30-60 minutes pre-bed.

At higher doses (3-6g) some users report a noticeable mild calm — described as "settling" rather than sedating. Distinct from theanine (which is more cognitive smoothness) and from magnesium (which is more muscular relaxation). No euphoria, no cognitive sharpening, no "feel" comparable to caffeine or modafinil. People who expect a noticeable subjective effect are usually disappointed; people who track HRV, resting heart rate, or sleep latency may see slow drift in the right direction.

Onset to felt benefit: variable, often days to weeks of consistent use rather than acute. Some endurance benefit may be present acutely (single-dose meta-analysis evidence) but subjectively imperceptible.

• Tolerance buildup: minimal to none. Mechanism is structural/regulatory (osmolyte, mitochondrial tRNA, cardiac ion handling) rather than receptor-mediated downregulation.
• Recommended cycle: None needed for daily use. Encyclopedia confirms: "Daily, no cycling needed."
• Reset protocol: N/A.

Synergistic with

• magnesium-glycinate: Both calcium-modulating, both calming, both stack-safe with V4. Convergent on cardiac/neuronal excitability reduction. Common pre-bed pairing.
• l-theanine: Both GABAergic (theanine via more complex mechanism: GABA + glutamate modulation + alpha-wave). Together with taurine = layered calm without sedation. Caffeine + theanine + taurine is the energy-drink trifecta and is genuinely synergistic.
• alcar: Mitochondrial-energy synergy. ALCAR provides acetyl groups + carnitine for fatty-acid β-oxidation; taurine maintains mt-tRNA function and protects against oxidative damage. Both at 500mg-1g AM is a clean mitochondrial pair.
• agmatine: Both NMDA-modulating in mild ways (taurine is anti-excitotoxic; agmatine is direct NMDA antagonist). Both daily-safe. Stack adds calm + neuroprotection.
• nad-plus precursors (NMN, NR): Mitochondrial co-support. NAD+ drives sirtuin and ETC function; taurine maintains mt-tRNA translation and protects ETC from oxidative load. Theoretical strong synergy, light empirical data.
• caffeine: Classic. Taurine smooths the sympathetic edge of caffeine and may extend cardiac tolerability. Not pharmacokinetically synergistic — independent additive cognitive effects per 2025 Tandfonline meta-analysis.
• creatine: Both cell-volume / osmolyte agents. No documented antagonism. Both daily-safe.
• beta-alanine: Standard combat-sport stack. No known interaction; both buffer-side support.

Avoid stacking with

• Lithium: Reduce or discontinue taurine if on lithium therapy. Theoretical reduction of lithium clearance.
• High-dose GABAergics (benzos, phenibut, baclofen): Not contraindicated but additive sedation possible at high taurine doses. Real risk is low but worth flagging.

Neutral / safe co-administration

• All V4 stack components: NAC, citicoline, magnesium glycinate + threonate, DHA, PS, curcumin, rhodiola, theanine, glycine, D3+K2, beta-alanine, vitamin C, creatine.
• All V5 planned stack additions: modafinil, bromantane, Adamax/Semax, ALCAR, apigenin, astaxanthin, l-tryptophan.

• Lithium: Possible reduced clearance via taurine's mild diuretic activity. Monitor lithium levels if combining; conservative recommendation is to avoid.
• Antihypertensives: Additive BP reduction. Patients on multiple antihypertensives should check BP weekly when starting taurine to avoid hypotension. Not a contraindication, just monitoring.
• CYP enzymes: Taurine is not a notable CYP inducer or inhibitor. No relevant interactions with modafinil, bupropion, or other CYP-metabolized stack drugs.
• Contraceptives: No documented interaction.
• Metformin / SGLT2 inhibitors: Additive glucose-lowering effect; check blood sugar if combining and diabetic.

Taurine endogenous synthesis is governed by CDO1 (rate-limiting) and CSAD in the cysteine→hypotaurine→taurine pathway.

• CDO1: Rate-limiting cysteine dioxygenase. Polymorphisms affecting CDO1 expression theoretically alter endogenous taurine production. Direct human PGx data is sparse — most knowledge comes from CDO1-knockout mouse models showing dramatic reduction in plasma + tissue taurine. Variants in human CDO1 are associated with sulfur amino acid metabolism phenotypes but no clinically actionable supplementation guidelines exist yet.
• CSAD: Cysteine sulfinic acid decarboxylase. In humans, CSAD is regulated less strongly than in mice (the bile-acid feedback loop via FXR/HNF4α is mouse-specific). This explains why humans rely more on dietary taurine and have lower endogenous synthesis capacity than rodents — and why mouse longevity data may not translate cleanly.
• Practical implication: People with low-meat / vegan diets are likely to have lower baseline taurine (taurine is concentrated in animal tissue, especially shellfish, beef, dark poultry meat). Endogenous synthesis is modest — supplementation is more functionally relevant in low-intake populations.
• 23andMe relevance for Dylan: Once results land (~June 5-15, 2026), check for CDO1 / CSAD / TauT (SLC6A6) variants. No actionable dosing change expected at 1-2g/day — the dose is far above any plausible synthetic shortfall — but worth filing for context.

Recommended for Dylan: NOW Foods 1000 mg caps via iHerb (already in V4 supplier flow) OR Nootropics Depot powder if going bulk. Cost is trivially small (<$10/mo).

• Baseline (before starting): Resting heart rate, BP (sit/stand if available), fasting glucose + HbA1c, lipid panel, hsCRP. If clinical concern: echo/LVEF (only if cardiac context), liver panel.
• During use: Resting heart rate (weekly via ring), BP (monthly cuff), HRV trend (Colmi/Oura/Whoop), sleep onset latency self-report. At 8-12 weeks: repeat fasting glucose, HbA1c, lipids if cardiometabolic was the goal.
• Post-cycle: N/A (not cycled). For people stopping: re-check BP and resting HR over 2-4 weeks to see if values drift back.
• Plasma taurine (rare, optional): Available via specialty labs (LabCorp/Quest amino acid panel). Useful in research contexts; not actionable for routine use.